Table 4 Incidence of adverse events of special interest for bevacizumab
N = 12 | CTC-AE grade (Ver. 4.03) | ||||
|---|---|---|---|---|---|
1 | 2 | 3 | 4 | Total (%) | |
Hypertension | 2 | 2 | 0 | 0 | 4 (33 %) |
Epistaxis | 3 | 0 | 0 | 0 | 3 (25 %) |
Throat Bleeding | 1 | 0 | 0 | 0 | 1 (8 %) |
Stroke | 0 | 1 | 0 | 0 | 1 (8 %) |
Perforation (colon) | 0 | 0 | 1 | 0 | 1 (8 %) |
Proteinuria | 1 | 0 | 0 | 0 | 1 (8 %) |
Bronchopulmonary bleeding | 0 | 0 | 0 | 0 | 0 (0 %) |
AESI (Most severe grade) | 4 | 2 | 1 | 0 | 7 (58 %) |